Chinese Biotech Duo Eyes $2.8 Billion Singapore Expansion
Chinese contract drugmakers Wuxi AppTec Co. Ltd. and Wuxi Biologics Cayman Inc. have each unveiled a 10-year investment plan to expand their presence in Singapore — a boost to the Southeast Asian country’s effort to establish itself as a global biomedical manufacturing hub.
Wuxi Biologics was spun off from the large molecule drug subsidiary of Wuxi AppTec to list in Hong Kong in 2017. Already Shanghai-listed Wuxi AppTec landed in Hong Kong the following year.
- MOST POPULAR